Evidence map›Paper›PMID 41625378›Full record

ArticleMaterials today. Bio2025

Harnessing nanozymes as next-generation antimicrobial agents: From mechanisms to therapeutic strategies.

Shanshan Feng, Zhaoxun Wang, Yibin Zhang, Ling Mei, Zhenxing Wang

Erratum issuedAbstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Shanshan FengEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Zhaoxun WangInfectious diseases Department, Traditional Chinese Medicine Hospital of Meishan, Meishan, 620020, China.
Yibin ZhangEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Ling MeiEngineering Research Center for Pharmaceuticals and Equipments of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
Zhenxing WangTraditional Chinese Medicine Hospital of Meishan, Meishan, 620020, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The escalating threat of antimicrobial resistance (AMR) and the limited efficacy of conventional antibiotics have intensified the search for alternative therapeutic strategies. Nanozymes, nanomaterials with enzyme-mimicking properties, have emerged as a promising class of antimicrobial agents due to their broad-spectrum activity, tunable catalytic functions, and resistance-independent mechanisms. This review provides a comprehensive overview of the recent advances in nanozyme-based antimicrobial applications, focusing on their classification, catalytic mechanisms, and multifaceted antimicrobial actions. We highlight the unique advantages of nanozymes, including their ability to generate reactive oxygen species (ROS), disrupt biofilms, modulate infection microenvironments, and synergize with other therapeutic modalities. Furthermore, we discuss their performance in various infection models, such as skin and soft tissue infections, oral infections, ocular infections, gastrointestinal infections, respiratory infections, urinary tract infections, systemic infections, diabetic wounds, chronic ulcers, and fungal infections. Finally, we address current challenges in clinical translation, including biosafety, dose control, and scalable production. This review underscores the transformative potential of nanozymes in combating drug-resistant pathogens and offers insights into future directions for their clinical development.

Indexed as

Antimicrobial therapyBiofilmCatalytic mechanismNanozymesReactive oxygen species

Identifiers

PMID41625378
PMCPMC12859674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.